All News
TM61 at #ACR23
23 yo M p/w ~3mo of sternal swelling
- US probable abscess, drained + multiple abx w/ no improvement
- XR R shoulder + L elbow nl but MRI abn
- MRI L elbow: possible osteomyelitis (OM)
- MRI R shoulder; clavicular osteolysis
- Bone Bx clavicle + L Ulna: Chronic… https://t.co/QkLV9ce7hs https://t.co/o8zfu59MRP
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Pain sensitization in #OA in the MOST study. Biomechanical forces- ground reaction forces may
Alter nociceptive signaling but was not associated with pain.
Walking evoked knee pain specifically tested - no diff @RheumNow #ACR23 https://t.co/G7TXuwJ2EQ
Bella Mehta bella_mehta ( View Tweet)
Tapering ABA vs. stable dose ABA in RA
No diff in DAS28 remission at 2 years
But…
Only in patients receiving concomitant MTX
Those tapering ABA mono also experience higher functional important
Of note: not an RCT
@RheumNow #ACR23 ABST2542 https://t.co/yycCDTnRiF
Aurelie Najm ( View Tweet)
#Lupus #nephritis - #inflammatory #fibrosis predicts #renal damage on #kidney #bx @ACRheum @RheumNow #ACR23 #2552 - similar in CRF from #Diabetes etc Biomarker is i-IFTA - same as other CRF diseases https://t.co/2LNn5Wn7rJ
Janet Pope ( View Tweet)
How does CAR-T work and how many do we have? Dr. Sadelain details the history, manufacturing, and 6 currently FDA-approved CAR-T products. #ACR23 @RheumNow https://t.co/a4jGfhT8EU
Dr. Rachel Tate ( View Tweet)
Dr. @drpnash @RheumNow
➡️Difficult to treat Axial SpA ;
23,0000 🧍♀️🧍:
1-Failure of 3 biolo - targ synth, or different mechanism of action.
2- Around 10% of patients.
1-Female.
2-Peripheral arthritis.
3-Psoriasis
4-Lipid , HTN, Smoking.
https://t.co/B99TcXjjiF…
#ACR23
Nouf Al hemmadi ( View Tweet)
Got to get a pic with the very busy man Dr @RheumNow John “Jack” Cush at his booth at @ACRheum #ACR23 #ACRambassador . Make sure to follow RheumNow to keep up on important rheum matters https://t.co/rgWvRr0Dln
Donald Thomas, MD lupuscyclopedia ( View Tweet)
The ADIRA trial showed no significant difference in change in DAS28 bet grps in the adjusted analysis.
Intervention included food delivery svc & probiotic shot
Limitations included study design issues such small sample size
#ACR23 @RheumNow @rheumarhyme https://t.co/J6LEb0yONS
sheila ( View Tweet)
Don’t forget:
👉anti-HMGCR Ab in patients with immune mediated necrotizing myositis (may be assc with statins)
👉Anti-synthetase Ab assc with ILD, anti-synthetase syndrome #Rheum #BoardQuestion https://t.co/pBAADeR9ON
TheDaoIndex KDAO2011 ( View Tweet)
Persistence of IL-17i vs. TNFi in PsA treatment
Large database study
Persistence of IL-17i slightly greater than TNFi over 12 months
Are IL-17i a better longterm strategy for PsA pts?
@RheumNow #ACR23 Abs# 2240 https://t.co/9km5XgXcLE
Robert B Chao, MD ( View Tweet)
#VEXAS is still hot at #ACR23 - 245K whole genome sequencing data from #NIH All of US - 74 with somatic mutation UBA1
Increased asthma, Tietze’s syndrome and neutropenia
Hemoglobin similar in cases and controls
@rheumnow #abstL03 https://t.co/A374w60e6H
Bella Mehta bella_mehta ( View Tweet)
Review of the limitations and possible toxicities with CAR-T treatment. ICANs and CRS, while treatable, are very important to educate and understand. This is part of the intersection of heme/onc and rheum. https://t.co/itbwLdHuqf
Dr. Rachel Tate ( View Tweet)
RheumNow’s expanded coverage of the #ACR23 is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty.
Dr. John Cush RheumNow ( View Tweet)
Rector et al. Pregnancy outcomes in vasculitis. More spontaneous abortion, elective termination, ectopic & molar pregnancy, x2 preterm delivery. Preeclampsia in 12%. Worse again in small vessel vasculitis Abstr#2425 #ACR23 @RheumNow https://t.co/cotncE16ma https://t.co/QoJpJIHJfJ
Richard Conway ( View Tweet)
#ACRBest https://t.co/nx3bzhmeBW
Aurelie Najm ( View Tweet)
There is a dose, duration and recency-dependent relationship between previous GC use and MACE. GC doses 5mg/day, durations of 30 days, and use one year prior to MACE were all associated with an increased risk of MACE, Wallace B Abst#2430 #ACR23 #ACRBest https://t.co/2ExboBvo2W https://t.co/FuqXdFFwqP
Dr. Antoni Chan ( View Tweet)
What % of pts in #RCTs in #SLE go in to #LLDAS - Pooling 5 RCTs - starting on #belimumab vs #placebo? More w #bDMARD @RheumNow @ACRheum #ACR23 abst#2551. True w DORIS - #lupus #rem but overall lower rates in each group https://t.co/VPZrYCVjof
Janet Pope ( View Tweet)
The perks of a conference in San Diego
The midday break with a view 🌞 🛥️
@RheumNow #ACR23 https://t.co/IRh7IRpWJz
Aurelie Najm ( View Tweet)
A#2545 IV SEC for SpA #ACR23 @Rheumow
Approved by FDA, though diff dose
Who: Medicare/cost/QoL benefit for IV or obese (wt based dose)
W16: 41% ASAS40 v 23% PBO
W16, PBO switched to SEC. Efficacy W52 (SEC 67%, PBO/Sec 75%)
SAE 6%, discontinuation 3.5%
#ACRBest https://t.co/ruW0ys49gk
Eric Dein ( View Tweet)
Development of New classification crieteria to target patients earlier in thier #OA disease course!
One tatget molecule will not solve this heterogeneous disease! @rheumnow #ACR23 https://t.co/waynA6RdUg
Bella Mehta bella_mehta ( View Tweet)